2-(Diethylamino)ethane-1-sulfonamide | 1177381-23-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 2-(Diethylamino)ethane-1-sulfonamide
• 英文别名: 2-(diethylamino)ethanesulfonamide
• CAS: 1177381-23-5
• 化学式: C₆H₁₆N₂O₂S
• 分子量: 180.271
• InChiKey: PLLHYBGLFFDOFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-hydroxy-4-(7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[e][1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-pyridazin-3-one 、 2-(Diethylamino)ethane-1-sulfonamide 在 copper(l) iodide 、 肌氨酸 、 磷酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 2-(diethylamino)-N-[3-[5-hydroxy-2-isopentyl-3-oxo-6-(2-thienyl)pyridazin-4-yl]-1,1-dioxo-4H-1$l^{6},2,4-benzothiadiazin-7-yl]ethanesulfonamide
  参考文献：
  名称：

  Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments

  摘要：

  5-Hydroxy-3(2H)-pyridazinone derivatives were investigated as inhibitors of genotype 1 HCV NS5B polymerase. Lead optimization led to the discovery of compound 3a, which displayed potent inhibitory activities in biochemical and replicon assays [IC50 (1b) < 10 nM; IC50 (1a) = 22 nM; EC50 (1b) = 5 nM], good stability toward human liver microsomes (HLM t(1/2) > 60 min), and high ratios of liver to plasma concentrations 12 h after a single oral administration to rats. (c) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2008.02.072

文献信息

• [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases
  申请人：Rice Ken

  公开号：US20080188482A1

  公开（公告）日：2008-08-07

  The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

  本发明提供了式（I）的化合物和抑制激酶的方法，更具体地是p70S6激酶，更优选的是p70S6，Akt-1和Akt-2激酶的抑制剂。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖，分化，程序性细胞死亡，迁移，化学入侵和代谢）的化合物。本发明的化合物抑制，调节和/或调节与上述细胞活动变化相关的激酶受体信号转导途径，本发明包括含有这些化合物的组合物和使用它们治疗依赖于激酶的疾病和情况的方法。
• Methods of using MEK inhibitors
  申请人：Lamb Peter

  公开号：US20080166359A1

  公开（公告）日：2008-07-10

  The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

  本发明提供了一种通过给予I式化合物或其药学上可接受的盐或溶剂与其他癌症治疗相结合的方法来治疗癌症的方法。
• S1P1 Agonists and Methods of Making And Using
  申请人：Canne Bannen Lynne

  公开号：US20100160369A1

  公开（公告）日：2010-06-24

  The invention is directed to Compounds of Formula I: as well as methods of making and using the compounds.

  本发明涉及式I的化合物，以及制备和使用该化合物的方法。
• Sulfonamides and uses thereof
  申请人：Distefano Peter

  公开号：US20050261332A1

  公开（公告）日：2005-11-24

  Compounds of formulas (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

  式 (I)、(II)、(III) 和 (IV) 的化合物 以及通过施用式 (I)、(II)、(III) 或 (IV) 化合物治疗疾病的方法在此进行了描述。疾病的例子包括肿瘤性疾病、脂肪细胞相关疾病、神经退行性疾病和代谢性疾病。
• Sufonamides and Uses Thereof
  申请人：Saunders Jeffrey O.

  公开号：US20080261970A1

  公开（公告）日：2008-10-23

  Compounds of formula (I), including methods of making and methods of using are described in formula (I).